Tegafur-Uracil
Tegafur-Uracil (UFT; BMS-200604) is an effective oral chemotherapy drug based on fluoropyrimidine. Tegafur-Uracil inhibits thymidylate synthase. Tegafur-Uracil can be used in combination with leucovorin (LV) and polysaccharide K (PSK) for research on solid tumors[1][2].
Product Specifications
CAS Number
[74578-38-4]
Product Name Alternative
UFT; BMS-200604
UNSPSC
12352005
Target
Thymidylate Synthase
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tegafur-uracil.html
Purity
99.77
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1C=CNC(N1)=O.O=C2NC(N(C3OCCC3)C=C2F)=O
Molecular Formula
C12H13FN4O5
Molecular Weight
312.25
References & Citations
[1]Casado E, et al. UFT (tegafur-uracil) in rectal cancer. Ann Oncol. 2008;19 (8) :1371-1378.|[2]Ryoji Katoh, et al. Enhancement of antitumor effect of tegafur/uracil (UFT) plus leucovorin by combined treatment with protein-bound polysaccharide, PSK, in mouse models. Cell Mol Immunol. 2007 Aug;4 (4) :295-9.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
